News
Hosted on MSN2mon
FDA approves scPharmaceuticals’ Furoscix sNDA for oedema in CKDThe effect on the distal tubule is not dependent on carbonic anhydrase or aldosterone’s inhibitory effect. The therapy is contraindicated in individuals with anuria or with a history of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results